Press Releases

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year - - Total Epidiolex ®  preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year – -

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive

EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized CARLSBAD, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid

LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham

- Meeting Highlights Include New Long-Term D ata in Tuberous Sclerosis Comple x - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S.

LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore

- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed

LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel

- Total revenue increased 51 percent to $ 137.1 million –   - Epidiolex for seizures associated with TSC launch ed in the U.S. - - Nabiximols Phase 3 program in MS spasticity now recruiting - - Conference call today at 8 :30 a .m. E S T - LONDON and CARLSBAD, Calif., Nov.

CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that